**To the editor:** As the specialist laboratory providing chikungunya virus (CHIKV) diagnostics to the National Health Service (NHS) across the United Kingdom (UK), we read with interest the rapid communication by Javelle et al. \[[@r1]\] regarding the chikungunya outbreak in Thailand at the beginning of 2019.

Alongside the two UK cases reported in the paper, we diagnosed a further two CHIKV infections in travellers returning to the UK from Thailand in the same timeframe (the molecular assay used is based on the method of Edwards et al. \[[@r2]\], rather than Pastorino et al. \[[@r3]\], as was incorrectly indicated in the published paper). Case 1 recovered completely within 3 weeks, but case 2, an older individual, has been referred to rheumatology for management of persistent arthralgia, which has improved after a course of steroids (Table).

###### Overview of two further confirmed chikungunya cases among travellers returning from Thailand to the UK, January--February 2019 (n = 2)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case   Reporting Country   Place visited   Period of exposure            Age^a^\   Underlying conditions   Date of onset   Clinical acute symptoms                                   Outcome                 Recovery status as at 9 May 2019   Diagnosis method\
                                                                           (years)                                                                                                                                                                (positive tests)
  ------ ------------------- --------------- ----------------------------- --------- ----------------------- --------------- --------------------------------------------------------- ----------------------- ---------------------------------- ---------------------------------------------------------------------------------------
  1      UK                  Unknown         December 2018--January 2019   40        None                    January 2019    Rash, fever, headache, arthralgia, myalgia                Recovered               Yes                                CHIKV RT-PCR \[[@r2]\] and anti-CHIKV IgM ELISA (Euroimmun, Lubeck, Germany) on day 5

  2      UK                  Koh Lanta       Unknown--\                    60        None                    Unknown         Fever, headache and synovitis of small and large joints   Persistent arthralgia   No                                 CHIKV RT-PCR \[[@r2]\]
                                             February 2019                                                                                                                                                                                        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

UK: United Kingdom.

^a^Rounded to the nearest 5-year group.

The two additional cases we diagnosed were not reported to any of the data collection networks for the surveillance of travel-related illness. This indicates a limitation of surveillance networks that receive their data from the medical centres where patients are clinically assessed, rather than the laboratories that diagnose the infections. With this in mind, it is likely that there were more chikungunya infections from Thailand diagnosed in specialist laboratories across Europe in the first two months of 2019 than were reported to EuroTravNet/GeoSentinel or TropNet.

Currently, national public health bodies across the European Union/ European Economic Area (EU/EEA) report laboratory diagnoses of CHIKV infection to the European Centre for Disease Prevention and Control on an annual basis via the European Surveillance System (TESSy) \[[@r4]\]. Timely information on the numbers and sources of imported infections is therefore not available. We wonder whether a laboratory-based system of monthly or semi-monthly notifications of imported infections such as dengue and chikungunya could be considered.

TESSy is a system for the collection, analysis and dissemination of data on communicable diseases. Indeed, there is precedent for TESSy to be used for more regular reporting of data; at the time of the Zika virus (ZIKV) outbreak in 2016, ZIKV diagnoses data from across the EU/EEA were collected weekly for real-time surveillance. Direct laboratory notifications might contribute less clinical data than clinician notifications of laboratory-diagnosed imported infections such as chikungunya and dengue; nevertheless, we suggest that the routine availability of timely information regarding the countries of origin of CHIKV and dengue virus infections imported into Europe would be invaluable to providers of both pre-travel advice and healthcare for returning travellers.
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